• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在人喉表皮样癌细胞（HEp-2）和非洲绿猴肾细胞（Vero）培养物中进行脊髓灰质炎病毒和脊髓灰质炎抗体检测。

Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures.

作者信息

Albrecht P, Enterline J C, Boone E J, Klutch M J

出版信息

J Biol Stand. 1983 Apr;11(2):91-7. doi: 10.1016/s0092-1157(83)80031-6.

DOI:10.1016/s0092-1157(83)80031-6
PMID:6306012
Abstract

HEp-2 cell cultures were about three to 30 times more sensitive for poliovirus titration than Vero cells. Attenuated strains induced a complete cytopathic effect in HEp-2 but not in Vero cells. For polio antibody titration, HEp-2 and Vero cells were equally suitable. A high degree of sensitivity and reproducibility of virus neutralization was achieved in tests utilizing a low virus dose and serum-virus incubation overnight at 36 degrees C. Staining of infected trays with crystal violet obviated reading of viral CPE under the microscope and expedited the evaluation of larger-scale tests.

摘要

人喉表皮样癌细胞（HEp-2）培养物用于脊髓灰质炎病毒滴定的敏感性比非洲绿猴肾细胞（Vero细胞）高约3至30倍。减毒株在HEp-2细胞中可诱导完全细胞病变效应，但在Vero细胞中则不会。对于脊髓灰质炎抗体滴定，HEp-2细胞和Vero细胞同样适用。在使用低病毒剂量且血清与病毒在36℃孵育过夜的试验中，实现了高度的病毒中和敏感性和可重复性。用结晶紫对感染的培养板进行染色，无需在显微镜下读取病毒致细胞病变效应（CPE），并加快了大规模试验的评估。

相似文献

1
Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures.在人喉表皮样癌细胞（HEp-2）和非洲绿猴肾细胞（Vero）培养物中进行脊髓灰质炎病毒和脊髓灰质炎抗体检测。
J Biol Stand. 1983 Apr;11(2):91-7. doi: 10.1016/s0092-1157(83)80031-6.
2
Standardization of poliovirus neutralizing antibody tests.脊髓灰质炎病毒中和抗体检测的标准化
Rev Infect Dis. 1984 May-Jun;6 Suppl 2:S540-4. doi: 10.1093/clinids/6.supplement_2.s540.
3
Conventional and enhanced plaque neutralization assay for polio antibody.脊髓灰质炎抗体的常规及强化斑块中和试验
J Virol Methods. 1983 Apr;6(4):193-202. doi: 10.1016/0166-0934(83)90046-0.
4
A modified ELISA technique for the titration of antibodies to polio virus as an alternative to a virus neutralization test.
J Virol Methods. 1983 Apr;6(4):233-9. doi: 10.1016/0166-0934(83)90050-2.
5
A micrometabolic inhibition test for the estimation of poliovirus neutralizing antibodies.一种用于评估脊髓灰质炎病毒中和抗体的微量代谢抑制试验。
Bull World Health Organ. 1972;47(2):171-5.
6
Radiometric cytolysis inhibition assay, a new rapid test for neutralizing antibodies to intact and trypsin-cleaved poliovirus.放射细胞溶解抑制试验，一种用于检测针对完整和胰蛋白酶裂解脊髓灰质炎病毒的中和抗体的新型快速检测方法。
J Clin Microbiol. 1989 Apr;27(4):709-15. doi: 10.1128/jcm.27.4.709-715.1989.
7
Rapid methods for identification of poliovirus isolates and determination of polio neutralizing antibody titers in human sera.
J Virol Methods. 2002 Mar;101(1-2):189-96. doi: 10.1016/s0166-0934(01)00437-2.
8
Automated microtransfer technique for the assay of poliovirus- and mumps virus-neutralizing antibodies.用于检测脊髓灰质炎病毒和腮腺炎病毒中和抗体的自动化微量转移技术。
Appl Microbiol. 1974 Dec;28(6):968-71. doi: 10.1128/am.28.6.968-971.1974.
9
Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on Vero cells or on primary monkey kidney cells.用Vero细胞或原代猴肾细胞制备的两种口服脊髓灰质炎疫苗对婴儿进行接种后脊髓灰质炎病毒排泄情况的比较研究。
J Med Virol. 1997 May;52(1):50-60.
10
Antipoliomyelitis immunity status among a population that was regularly vaccinated 11-12 years before.11至12年前定期接种疫苗人群中的抗脊髓灰质炎免疫状况。
Eur J Epidemiol. 1991 Nov;7(6):605-11. doi: 10.1007/BF00218669.

引用本文的文献

1
Application of MPBT Assay for Multiplex Determination of Infectious Titers and for Selection of the Optimal Formulation for the Trivalent Novel Oral Poliovirus Vaccine.MPBT 测定法在多价新型口服脊髓灰质炎疫苗感染滴度的多重测定及最佳配方选择中的应用。
Viruses. 2024 Jun 14;16(6):961. doi: 10.3390/v16060961.
2
Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine.评价含脊灰灭活疫苗和二价口服脊灰减毒活疫苗的基础免疫程序的免疫原性。
BMC Infect Dis. 2024 May 28;24(1):535. doi: 10.1186/s12879-024-09389-8.
3
Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study.
在印度健康婴儿中，六价白百破-脊髓灰质炎灭活疫苗-乙肝-结合型b型流感嗜血杆菌疫苗（DTwP-IPV-HB-PRP∼T）的批次间一致性以及在6-8周、10-12周和14-16周龄时与口服轮状病毒疫苗共同接种时，与单独的白百破-乙肝-结合型b型流感嗜血杆菌疫苗（DTwP-HB-PRP∼T）和脊髓灰质炎灭活疫苗抗原匹配疫苗相比的非劣效性：一项多中心、随机、对照研究。
Vaccine X. 2022 Sep 13;12:100216. doi: 10.1016/j.jvacx.2022.100216. eCollection 2022 Dec.
4
Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12-24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in India.在印度健康婴儿中，12至24月龄时接种六价白百破-脊髓灰质炎灭活疫苗-乙肝-结合疫苗（DTwP-IPV-HB-PRP∼T）与分别接种白百破-乙肝-结合疫苗（DTwP-HB-PRP∼T）和脊髓灰质炎灭活疫苗（IPV）后抗体持久性以及DTwP-IPV-HB-PRP∼T加强剂量的安全性和免疫原性。
Vaccine X. 2022 Jul 2;11:100190. doi: 10.1016/j.jvacx.2022.100190. eCollection 2022 Aug.
5
Immunogenicity of sequential poliovirus vaccination schedules with different strains of poliomyelitis vaccines in Chongqing, China: a cross-sectional survey.中国重庆不同型脊灰疫苗序贯免疫接种方案的免疫原性：横断面研究。
Hum Vaccin Immunother. 2021 Jul 3;17(7):2125-2131. doi: 10.1080/21645515.2020.1868269. Epub 2021 Mar 24.
6
Multiplex PCR-Based Neutralization (MPBN) Assay for Titers Determination of the Three Types of Anti-Poliovirus Neutralizing-Antibodies.基于多重聚合酶链反应的中和试验（MPBN）用于三种抗脊髓灰质炎病毒中和抗体滴度的测定
Vaccines (Basel). 2020 Mar 5;8(1):120. doi: 10.3390/vaccines8010120.
7
Multiplex PCR-based titration (MPBT) assay for determination of infectious titers of the three Sabin strains of live poliovirus vaccine.基于多重聚合酶链反应的滴定（MPBT）检测法，用于测定三株脊髓灰质炎活疫苗病毒株的感染滴度。
Virol J. 2019 Oct 28;16(1):122. doi: 10.1186/s12985-019-1233-6.
8
Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.使用灭活脊髓灰质炎疫苗（IPV）以及通过微针装置给予皮内分次剂量IPV进行早期免疫：一项随机对照试验。
Vaccine. 2015 Nov 27;33(48):6816-22. doi: 10.1016/j.vaccine.2015.09.039. Epub 2015 Oct 23.
9
Evaluating associations between vaccine response and malnutrition, gut function, and enteric infections in the MAL-ED cohort study: methods and challenges.在MAL-ED队列研究中评估疫苗反应与营养不良、肠道功能和肠道感染之间的关联：方法与挑战
Clin Infect Dis. 2014 Nov 1;59 Suppl 4(Suppl 4):S273-9. doi: 10.1093/cid/ciu611.
10
Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS (®)) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio (®)) given as a booster dose at 6 years of age.吸附型低剂量白喉、破伤风和灭活脊髓灰质炎联合疫苗（REVAXIS（®））与白喉、破伤风和灭活脊髓灰质炎联合疫苗（DT Polio（®））在6岁时作为加强剂量接种的免疫原性和安全性比较
Hum Vaccin. 2011 May;7(5):549-56. doi: 10.4161/hv.7.5.14982. Epub 2011 May 1.